Browse Category

Mergers & Acquisitions 4 November 2025 - 8 November 2025

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right of up to $20.65 per share, valuing the biotech at up to $10 billion. On Saturday, Novo Nordisk said it would not increase its bid and exited the race, citing legal and regulatory risks tied to its two‑step proposal. Metsera’s board said Pfizer’s amended agreement carries lower antitrust risk and recommended shareholders approve it at a Nov. 13 meeting. PR Newswire+1
8 November 2025
···
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters
8 November 2025
···
Sweetgreen (NYSE: SG) Cuts 2025 Outlook, Sells Spyce Robotics to Wonder for $186.4M After Weak Q3 — 11/7/2025

Sweetgreen (NYSE: SG) Cuts 2025 Outlook, Sells Spyce Robotics to Wonder for $186.4M After Weak Q3 — 11/7/2025

Sweetgreen reported third‑quarter FY2025 revenue of $172.4 million, down 0.6% year over year. Same‑store sales fell 9.5%, driven by an 11.7% drop in traffic and product mix, partly offset by 2.2% of price increases. Digital remained a majority of sales, with 35.3% coming through owned digital channels. Restaurant‑level profit margin compressed to 13.1% from 20.1% a year ago, and adjusted EBITDA swung to ‑$4.4M from +$6.8M. The company opened six net new restaurants in the quarter. Business Wire
7 November 2025
···
Archer Aviation (ACHR) Raises $650M, Moves to Buy Hawthorne Airport for $126M; Shares Slip After Q3 Update — Nov. 7, 2025

Archer Aviation (ACHR) Raises $650M, Moves to Buy Hawthorne Airport for $126M; Shares Slip After Q3 Update — Nov. 7, 2025

Archer Aviation Inc. unveiled a multi‑pronged update tied to its third‑quarter results: a $650 million equity raise, a deal to acquire control of Los Angeles’ Hawthorne Airport for $126 million, fresh flight‑test milestones for its Midnight eVTOL, and the closing of its Lilium patent portfolio purchase. The stock traded around $8.88 mid‑day as investors digested the capital raise and airport plan. Archer Aviation+1
7 November 2025
···
Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025

Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025

Brighthouse Financial, Inc. said this morning it has entered into a definitive agreement to be acquired by Aquarian Capital in an all‑cash deal valuing the company at approximately $4.1 billion, or $70.00 per share. The transaction would take the U.S. life insurer and annuity provider private and is expected to close in 2026, pending shareholder and regulatory approvals. Business Wire
6 November 2025
··
Strive Asset Management (ASST) prices upsized 12% preferred stock IPO to raise ~$160M; fresh Semler (SMLR) merger filing lands — Nov. 6, 2025

Strive Asset Management (ASST) prices upsized 12% preferred stock IPO to raise ~$160M; fresh Semler (SMLR) merger filing lands — Nov. 6, 2025

Strive, Inc.—the parent of Strive Asset Management, LLC—priced an upsized initial public offering of its Variable Rate Series A Perpetual Preferred Stock at $80 per share, expanding the deal to 2,000,000 shares for ~$160 million in expected gross proceeds. Settlement is slated for Monday, November 10, 2025, pending customary closing conditions. The preferred carries an initial 12% annual dividend, paid monthly beginning December 15, 2025, with a $100 stated amount and a framework that allows Strive to adjust the rate within defined limits. Barclays and Cantor are joint bookrunners, with Clear Street as co‑manager. Proceeds may fund Bitcoin purchases, income‑generating assets, share repurchases, debt reduction, and M&A. GlobeNewswire
6 November 2025
···
Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

FRISCO, Texas — Nov. 6, 2025. Shares of Comstock Resources, Inc. traded higher today after a week packed with catalysts: stronger third‑quarter results, progress on a $430 million asset sale, and a fresh technical tailwind as the stock’s Relative Strength rating ticked up. Midday, CRK changed hands around $21.14, up roughly 5.5%, within a 52‑week range of $11.41–$31.17. Reuters
6 November 2025
···
Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

1) Court clears the way for Metsera to pivot to Novo’s richer bid.On Wednesday evening, the Delaware Chancery Court denied Pfizer’s TRO request that sought to keep Metsera bound to its earlier merger agreement with Pfizer. In a same‑day statement, Pfizer argued the decision “does not address the merits” and vowed to pursue its claims in parallel antitrust litigation. BioSpace’s Thursday write‑up and the company’s press release confirm the ruling and Pfizer’s plan to keep fighting. BioSpace+1
6 November 2025
····
Google (GOOGL) Stock Today: Alphabet Rises on Apple–Siri AI Tie‑Up, Epic Play Store Settlement, and DOJ Nod for $32B Wiz Deal — Nov. 5, 2025

Google (GOOGL) Stock Today: Alphabet Rises on Apple–Siri AI Tie‑Up, Epic Play Store Settlement, and DOJ Nod for $32B Wiz Deal — Nov. 5, 2025

At a glance: Alphabet traded roughly 2% higher intraday as three catalysts landed on the same day: reports that Apple will use Google’s Gemini AI model to power a revamped Siri, a proposed settlement with Epic Games that reshapes Android app‑store rules, and word that Google’s $32 billion acquisition of cloud‑security firm Wiz cleared U.S. DOJ antitrust review. Reuters+3Reuters+3Reuters+3
5 November 2025
···
Cheer Holding (CHR) Stock Skyrockets on Buyout Bids – Inside the AI Innovator’s Rollercoaster Ride

Cheer Holding (CHR) Stock Skyrockets on Buyout Bids – Inside the AI Innovator’s Rollercoaster Ride

Cheer Holding, Inc. is a China-based provider of advanced mobile internet infrastructure and digital content platforms. Through its subsidiaries, Cheer offers advertising and content production services in the Chinese market. The company has built a suite of consumer apps and services under the “CHEERS” brand, aiming to create an integrated digital ecosystem. Its flagship offerings include CHEERS Video, CHEERS e-Mall, and CHEERS App which combines professionally-produced content with shopping features.
5 November 2025
··
Regional Banks Roar Back? Q3 Surprises, Mega‑Mergers—and the One Risk Still Haunting 2025

Regional Banks Roar Back? Q3 Surprises, Mega‑Mergers—and the One Risk Still Haunting 2025

After two straight Fed cuts took the policy range down again in late October, the October Senior Loan Officer Opinion Survey painted a nuanced picture: tighter C&I standards on balance, but basically unchanged CRE standards and stronger demand for mortgages and HELOCs. In other words, lending isn’t shutting down, but banks are still protective—especially on business credit. Federal Reserve
5 November 2025
·········
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alonereuters.comreuters.com. The share price is now hovering in the low $70sreuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emergedprnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4reuters.com – reflecting hundreds of percent in gains for early investors.
4 November 2025
···
Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Axcelis stock traded in the mid-$80s in early November 2025, rallying on earnings news. It closed around $86.24 on Nov 4, 2025, up about 5% for the day and roughly 8–9% over the two sessions surrounding its earnings report. This rebound comes after a soft October where ACLS had slid ~14% over a monthnasdaq.com, underperforming the tech sector. Even after the post-earnings pop, shares remain well below their 52-week high of ~$103 and about double the 52-week low near $40marketbeat.com, reflecting both the stock’s volatility and longer-term growth.
4 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market sharereuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performancereuters.comreuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal”reuters.com. This was weeks after Novo’s top shareholder overhauled its board to demand a faster turnaround in the weight-loss arenareuters.comreuters.com.
4 November 2025
···
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” and “vue”, reflecting a vision of insight-driven careen.wikipedia.org. As a spin-off, Kenvue took over J&J’s well-known retail brands, ranging from over-the-counter medicines to skincare and baby care. Today its portfolio spans three segmentsinvesting.com:
4 November 2025
···
1 … 14 15 16 17 18 … 20
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 BUY ON PULLBACK

Microsoft

NASDAQ: MSFT 94 / 100
#2 BUY

L3Harris Technologies

NYSE: LHX 90 / 100
#3 BUY

Xylem

NYSE: XYL 89 / 100
#4 BUY IN TRANCHES

Lam Research

NASDAQ: LRCX 87 / 100
#5 BUY ON WEAKNESS

GE HealthCare

NASDAQ: GEHC 84 / 100
View full portfolio
Editorial model selection. Not personalised advice.